Brenus Pharma

Brenus Pharma is a French clinical-stage biotech developing new generations of active immunotherapies against cancer.

Despite therapeutic advancements, fighting cancer requires new allies. Cancer cells can adapt under therapeutic pressure and escape from our immune system’s surveillance. This mechanism leads to treatment failure of 90% of patients with solid tumors.

Our discovery platform, Stimulated-Tumor-Cell (STC) doesn’t just fight cancer as it is today; it anticipates how cancer will evolve tomorrow, by mimicking relapsing conditions invitro, and training the patient’s immune system to recognize and destroy tumors, even as they change.

Brenus Pharma is on the brink of a breakthrough and will start its First in Human study in 2024 in colorectal cancer, killing 9.7 million of patient per year. We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.